Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

At the American College of Cardiology’s 74th Annual Scientific Session in Chicago, results from a study by Fretz et al., ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

New research indicates GLP1-RA medications do not increase thyroid cancer risk, reassuring users and clinicians. A new study, ...

As the indications and demand for glucagon-like peptide-1 (GLP-1) agonist drugs continue to expand, the real-world GLP-1 research and data-driven insights from Prime Therapeutics LLC (Prime) help ...

Weight loss is a key effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), but these drugs may also provide liver ...

Use of cutting-edge weight-loss drugs like Ozempic and Zepbound has increased dramatically among people with type 1 diabetes, raising safety concerns among experts, a new study says.

Key Takeaways More people with type 1 diabetes are severely obese and using GLP-1 drugs for weight lossExperts are concerned ...

Skinny jab? Try skinny juice. For centuries, it’s been enjoyed by people in South America — and it’s long been linked to ...

Corporation highlighted key data presentations at ACC.25 showcasing the mechanistic activity of eicosapentaenoic acid, EPA, on ...

While the exact mechanism is unknown, the data suggest a multitude of benefits independent of large weight loss.

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...